Table 1.
Demographics, comorbidity data and current medications of 4035 hospitalized patients with COVID-19 stratified according to vital status at study censoring date
| Characteristic | Alive (n = 2904) | Dead (n = 1131) | p | Total (N = 4035) |
|---|---|---|---|---|
| Sex | <0.001 | |||
| Male | 1666/2868 (58.1) | 767/1119 (68.5) | 2433/3987 (61.0) | |
| Female | 1202/2868 (41.9) | 352/1119 (31.5) | 1554/3987 (39.0) | |
| Pregnant female | 13/1136 (1.1) | 2/329 (0.6) | 0.395 | 15/1465 (1.0) |
| Gestational week, median (IQR) | 33 (17–38) | — | 33 (17–38) | |
| Age | ||||
| Median (IQR) (years) | 65 (51–75) | 79 (71–86) | <0.001 | 70 (56–80) |
| Distribution | <0.001 | |||
| 0–10 years | 13/2901 (0.4) | 2/1130 (0.2) | 15/4031 (0.4) | |
| 11–20 years | 18/2901 (0.6) | 0/1130 (0) | 18/4031 (0.5) | |
| 21–30 years | 89/2901 (3.1) | 2/1130 (0.2) | 91/4031 (2.3) | |
| 31–40 years | 210/2901 (7.2) | 5/1130 (0.4) | 215/4031 (5.3) | |
| 41–50 years | 373/2901 (12.9) | 18/1130 (1.6) | 391/4031 (9.7) | |
| 51–60 years | 483/2901 (16.6) | 68/1130 (6.0) | 551/4031 (13.7) | |
| 61–70 years | 624/2901 (21.5) | 167/1130 (14.8) | 791/4031 (19.6) | |
| 71–80 years | 675/2901 (23.3) | 357/1130 (31.6) | 1032/4031 (25.6) | |
| 81–90 years | 355/2901 (12.2) | 389/1130 (34.4) | 744/4031 (18.5) | |
| ≥91 years | 61/2901 (2.1) | 122/1130 (10.8) | 183/4031 (4.5) | |
| Country of birth | <0.001 | |||
| Spain | 2505/2819 (88.9) | 1065/1101 (96.7) | 3570/3920 (91.1) | |
| Other | 314/2819 (11.1) | 36/1101 (3.3) | 350/3920 (8.9) | |
| Ethnic group | <0.001 | |||
| Arab | 21/2821 (0.7) | 3/1094 (0.3) | 24/3915 (0.6) | |
| Asian | 16/2821 (0.6) | 2/1094 (0.2) | 18/3915 (0.5) | |
| Black | 12/2821 (0.4) | 0 | 12/3915 (0.3) | |
| Latin American | 166/2821 (5.9) | 20/1094 (1.8) | 186/3915 (4.7) | |
| White | 2578/2821 (91.4) | 1064/1094 (97.3) | 3642/3915 (93.0) | |
| Other | 28/2821 (1.0) | 5/1094 (0.5) | 33/3915 (0.8) | |
| Comorbidity | ||||
| Smoking history | <0.001 | |||
| Current smoker | 134/2123 (6.3) | 63/794 (7.9) | 197/2917 (6.7) | |
| Former smoker | 613/2123 (28.9) | 334/794 (42.1) | 947/2917 (32.5) | |
| Never smoked | 1376/2123 (64.8) | 397/794 (50.0) | 1773/2917 (60.8) | |
| Comorbid conditions | <0.001 | |||
| 0 | 848/2501 (33.9) | 52/938 (5.5) | 900/3439 (26.2) | |
| 1–2 | 1172/2501 (46.9) | 448/938 (47.8) | 1620/3439 (47.1) | |
| ≥3 | 481/2501 (19.2) | 438/938 (46.7) | 919/3439 (26.7) | |
| Types of comorbid conditions | ||||
| Hypertension | 1251/2885 (43.4) | 801/1125 (71.2) | <0.001 | 2052/4010 (51.2) |
| Chronic heart disease | 488/2875 (17.0) | 444/1119 (39.7) | <0.001 | 932/3994 (23.3) |
| Diabetes | 514/2884 (17.8) | 357/1118 (31.9) | <0.001 | 871/4002 (21.8) |
| Chronic pulmonary disease (not asthma) | 405/2879 (14.1) | 310/1116 (27.8) | <0.001 | 715/3995 (17.9) |
| Obesity | 316/2618 (12.1) | 181/988 (18.3) | <0.001 | 497/3606 (13.8) |
| Chronic neurologic disorder | 203/2886 (7.0) | 170/1116 (15.2) | <0.001 | 373/4002 (9.3) |
| Dementia | 124/2871 (4.3) | 191/1108 (17.2) | <0.001 | 315/3979 (7.9) |
| Asthma | 230/2884 (8.0) | 69/1116 (6.2) | 0.053 | 299/4000 (7.5) |
| Solid neoplasm (active) | 146/2882 (5.1) | 121/1116 (10.8) | <0.001 | 267/3998 (6.7) |
| Inflammatory disease | 148/2883 (5.1) | 83/1114 (7.4) | 0.005 | 231/3997 (5.8) |
| Chronic kidney disease stage 4 (eGFR <30 mL/min/1.73 m2) | 87/2882 (3.0) | 112/1118 (10.0) | <0.001 | 199/4000 (5.0) |
| Haematologic neoplasm (active) | 45/2885 (1.6) | 47/1120 (4.2) | <0.001 | 92/4005 (2.3) |
| Liver cirrhosis | 28/2882 (1.0) | 26/1116 (2.3) | 0.001 | 54/3998 (1.3) |
| HIV/AIDS | 20/2860 (0.7) | 6/1102 (0.5) | 0.589 | 26/3962 (0.7) |
| Current medications | ||||
| Angiotensin-converting enzyme inhibitors | 489/2878 (17.0) | 283/1105 (25.6) | <0.001 | 772/3983 (19.4) |
| Angiotensin II receptor blockers | 434/2879 (15.1) | 254/1108 (22.9) | <0.001 | 688/3987 (17.3) |
| Corticosteroids, inhaled | 303/2875 (10.5) | 184/1110 (16.6) | <0.001 | 487/3985 (12.2) |
| Corticosteroids, systemic | 113/2872 (3.9) | 95/1110 (8.6) | <0.001 | 208/3982 (5.2) |
| Antineoplastic agents | 59/2875 (2.0) | 49/1110 (4.4) | <0.001 | 108/3985 (2.7) |
| Biologic anti-inflammatory drugs | 69/2871 (2.4) | 27/1106 (2.4) | 0.944 | 96/3977 (2.4) |
| Antiretroviral drugs | 15/19 (78.9) | 6/6 (100.0) | 0.220 | 21/25 (84.0) |
Values are displayed as n/N with data (%).
eGFR, estimated glomerular filtration rate; IQR, interquartile range.